VelimirA.LuketicMD
Gastroenterology • Richmond, VAHepatology & Liver Transplantation
Professor, Internal Medicine, Virginia Commonwealth University, Medical College of Virginia School of Medicine
Dr. Luketic is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1250 E Marshall St
Richmond, VA 23298Phone+1 828-406-0804Fax+1 804-342-7619
Education & Training
Virginia Commonwealth University Health SystemFellowship, Gastroenterology, 1988 - 1991
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1985 - 1988
University of Alabama School of MedicineClass of 1985
Certifications & Licensure
VA State Medical License 1988 - 2026
MN State Medical License 1986 - 1988- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Fellow (FACG) American College of Gastroenterology
Clinical Trials
- LCP-Tacro vs. Azathioprine for the Treatment of Autoimmune Hepatitis Start of enrollment: 2007 Dec 01
- Pilot Study to Assess the Pharmacokinetics of Intravenous Nabi 5% Hepatitis B Immune Globulin (Boca HBVIg) Used in Combination With Lamivudine for Patients With Hepatitis B Virus (HBV) Associated Liver Disease Undergoing Liver Transplantation Start of enrollment: 1999 Nov 01
- Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis Start of enrollment: 2013 Aug 01
Publications & Presentations
PubMed
- 839 citationsClinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT valuesPouneh S. Mofrad, Melissa J. Contos, Mahmadul Haque, Carol Sargeant, Robert A. Fisher
Hepatology. 2003-06-01 - 724 citationsElafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Stephen A. Harrison, Sven Francque, Pierre Bedossa, Philippe Lehert
Gastroenterology. 2016-05-01 - 160 citationsMinimal effects of acute liver injury/acute liver failure on hemostasis as assessed by thromboelastographyR. Todd Stravitz, Ton Lisman, Velimir A. Luketic, Richard K. Sterling, Puneet Puri
Journal of Hepatology. 2012-01-01
Journal Articles
- Proton Pump Inhibitor Initiation and Withdrawal Affects Gut Microbiota and Readmission Risk in CirrhosisMichael Fuchs, Puneet Puri, Mohammad S Siddiqui, Douglas M Heuman, Jasmohan S Bajaj, Arun J Sanyal, Velimir Luketic, Richard K Sterling, Nature
Grant Support
- Studies Of Primary Sclerosing Cholangitis (STOPSC)National Center For Research Resources2009–2010
- Natural History Of Primary Biliary Cirrhosis After Treatment With MethotrexateNational Center For Research Resources2005–2010
- High Dose UDCA For Primary Sclerosing CholangitisNational Center For Research Resources2004–2010
- Database On PTS WHO Receive Orthotopic Liver Transplantation For HEP BNational Center For Research Resources2005–2008
- Ursodeoxycholic Acid &Methortrexate In Biliary CirrhosisNational Center For Research Resources2004–2005
- Database On PTS WHO Receive Orthotopic Liver TransplantNational Center For Research Resources2004
- HBIG As Immunoprophylaxis For Recurrent Hepatitis B Following OrthotoNational Center For Research Resources1999–2001
- Ursodeoxycholic Acid Treatment Of Primary Biliary CirrhosisNational Center For Research Resources1994–1997
- The Timing Of Liver TransplantationNational Center For Research Resources1992–1997
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
